Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 6/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700098 | 0.95 | BCL2 (0.41) | BCL2BCL2L1IRAK4SCN9ASMO | |
| SCHEMBL1959260 | 0.84 | IRAK4 (0.38) | BCL2IRAK4SCN9ALRRK2 | |
| Trifluoroacetic Acid SCHEMBL1700071 | 0.81 | IRAK4 (0.37) | IRAK4SCN9ALRRK2 | |
| SCHEMBL1700303 | 0.79 | SCN9A (0.41) | SCN9A | |
| SCHEMBL1700322 | 0.79 | ALDH1A1 (0.39) | BCL2SCN9ALRRK2ALDH1A1 | |
| SCHEMBL1700662 | 0.78 | CA2 (0.41) | BCL2SCN9ASMO | |
| SCHEMBL1701933 | 0.75 | BCL2 (0.42) | BCL2SCN9AALDH1A1 | |
| SCHEMBL1700545 | 0.75 | SCN9A (0.40) | BCL2SCN9A | |
| SCHEMBL1700543 | 0.75 | SCN9A (0.40) | BCL2SCN9A | |
| SCHEMBL1701186 | 0.75 | SCN9A (0.40) | BCL2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |